Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Camrelizumab in Advanced HCC
NCT04443309Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2020
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in hepatocellular carcinoma (HCC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate at 1 year. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04443309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443309.